The Latest Cardiac and Vascular News
Analysis Shows Treatment Effect of Omecamtiv Mecarbil Increased Progressively as Baseline Ejection Fraction Decreased SOUTH SAN FRANCISCO, Calif., May 17, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship […]
Phase 1 healthy volunteer study demonstrates that oral administration of IMB-101 is well tolerated and exhibits predictable pharmacokinetic characteristics Pre-clinical study showed that IMB-101 improves cardiac contractile function and fibrosis post-myocardial infarction, highlighting its therapeutic potential in the context of myocardial ischemia and heart failure BOSTON–(BUSINESS WIRE)–Imbria Pharmaceuticals, a clinical […]
AT-01 detected cardiac amyloid in AL and ATTR patients with known cardiac disease with 95% sensitivity AT-01 detected cardiac amyloid in patients with AL or ATTR amyloid with normal levels of serum NT-proBNP AT-01 has the potential to distinguish AL and ATTR amyloidosis based on organ distribution SOUTH SAN FRANCISCO, […]
Mavacamten, a potential first-in-class cardiac myosin inhibitor for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), showed improvement in health status compared to placebo at 30 weeks in EXPLORER-HCM trial Findings of new analysis published simultaneously in The Lancet PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced a new analysis of data […]
Minimally-invasive, implant-free technology for heart failure patients studied at 1 and 3 months AUSTIN, Texas–(BUSINESS WIRE)–Alleviant Medical Inc., a privately-held medical device company, today announced one-month and three-month follow up data from the first in human clinical study (ALLEVIATE-HF-1) of its technology for the treatment of heart failure with preserved […]
Positive results from the landmark PzF SHIELD IDE clinical trial reinforce safe and effective use in a real-world clinical practice of the world’s first non-drug-eluting, nanocoated coronary stent. SAN ANTONIO, May 13, 2021 /PRNewswire/ — CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its […]
TAMPA, Fla., May 12, 2021 /PRNewswire/ — Tampa General Hospital and USF Health’s Interventional Cardiology team has adopted new intravascular technology and successfully treated the first patient in the world. Tampa General has built a legacy as an early adopter of intravascular imaging for coronary intervention and continues to seek the newest and […]
Heart & Vascular Institute Expansion and Community Partnerships Lead to Decrease in Heart-Related Deaths EDGEWOOD, Ky., May 13, 2021 /PRNewswire/ — St. Elizabeth Healthcare is increasing access to quality cardiac care in the Northern Kentucky community with system-wide enhancements to the Heart & Vascular Institute (HVI), including the construction of a new, 67,000-square-foot facility in Edgewood and expansions to the […]
Gentle Ultrafiltration with Aquadex SmartFlow® Expands Options for Pediatric Patients EDEN PRAIRIE, Minn., May 13, 2021 (GLOBE NEWSWIRE) — Reaffirming its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload, Nuwellis, Inc. (Nasdaq: NUWE), formerly CHF Solutions, Inc., today announced that its […]
Study Evaluates the Safety and Feasibility of TherOx Supersaturated Oxygen (SSO2) Therapy in STEMI Patients presenting with Cardiogenic Shock CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today the U.S. Food and Drug Administration (FDA) has approved an investigational device […]
